100 Campus Drive
Unit 107
Scarborough, ME 04074
United States
Hodgkin lymphoma, Brentuximab vedotin, residual node radiation, response adapted therapy, pediatric, high-risk, frontline trial
acute lymphoblastic leukemia, hypodiploid, stem cell transplant
IKZF1, IKAROS, acute lymphoblastic leukemia, ALL, germline genetic variation, predisposition